MedDataX Logo

Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

NCT06861010 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-06-24

No results posted yet for this study

Summary

Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.

Conditions

  • Pancreatic Diseases

Interventions

OTHER

Placebo

Placebo tablets will have the same look and appearance of ondansetron.

DRUG

Ondansetron

ondansetron is commonly used as anti-emetics to prevent and treat chemotherapy-induced vomiting and nausea

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-12-20
Completion
2025-12-20

Countries

  • Egypt

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06861010 on ClinicalTrials.gov